Drug intelligence / Profile preview

ricin vaccine RVEc

Development stage: Phase 1
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RVEc is a genetically derived ricin A chain vaccine candidate developed to protect against ricin intoxication. It has been engineered to lack the toxic N-glycosidase activity of the native ricin toxin. The vaccine has demonstrated protective effects against aerosolized ricin holotoxin challenges in animal studies and has shown a favorable safety profile in both laboratory studies with human endothelial cells and in Phase 1 clinical trials.

Targets

RTA (Ricin A chain)

Beyond the preview

Go deeper on ricin vaccine RVEc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ricin vaccine RVEc.

Explore the full profile